CAMBRIDGE, Mass., June 21, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases, announces that it has received a notice of delisting from Nasdaq. The staff of the Listing…